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Abstract
Background: Almost all studies of pathologic fractures have been conducted based on patients with tumours and
hospital-based data; however, in the present study, a nationwide epidemiological survey of pathologic fractures in
Taiwan was performed and the medical utilization was calculated.
Methods: All claimants of Taiwan’s National Health Insurance (NHI) Program in 2008 were included in the target
population of this descriptive cross-sectional study. The registration and inpatient expenditure claims data by
admission of all hospitalized subjects of the target population were examined and the concomitant International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes were evaluated and
classified into seven major categories of fracture.
Results: A total of 5,244 incident cases of pathologic fracture were identified from the 2008 hospitalized patient
claims data. The incidence of pathologic fracture of the humerus, distal radius/ulna, vertebrae, femoral neck, other
part of the femur, and tibia/fibula was 0.67, 0.08, 10.58, 1.11, 0.56, and 0.11 per 100,000 people, respectively, and
patients with those fractures were hospitalized for 43.9 ± 42.9, 31.1 ± 32.9, 29. 4 ± 34.4, 43.3 ± 41.2, 42.4 ± 38.1,
and 42.0 ± 32.8 days, respectively, incurring an average medical cost of US$11,049 ± 12,730, US$9,181 ± 12,115, US
$6,250 ± 8,021, US$9,619 ± 8,906, US$10,646 ± 11,024, and US$9,403 ± 9,882, respectively. The percentage of
patients undergoing bone surgery for pathologic fracture of the humerus, radius/ulna, vertebrae, femoral neck,
other part of the femur, and tibia/fibula was 31.2%, 44.4%, 11.3%, 46.5%, 48.4%, and 52.5% respectively.
Conclusions: Comparing Taiwan to other countries, this study observed for Taiwan higher medical utilization and
less-aggressive surgical intervention for patients hospitalized with pathologic fractures.
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Background
The skeleton is the third most common target of meta-
static cancer and can be one of the earliest sites affected.
Ultimately, 60-84% of all cases of metastatic disease
invade the bone, and approximately 70% of these
patients experience bone pain [1]. Patients with
metastatic cancer involving the bone are also at
increased risk of fractures, spinal cord compression,
hypercalcemia and immobility, resulting in substantial
medical-associated morbidities [2]. Patients with long-
bone or pelvic-girdle metastases are indicated for surgi-
cal treatment if they suffer a pathologic fracture,
impending fracture or intractable pain [3], and surgical
treatment of spinal metastases is indicated for patients
with spinal instability or spinal cord compression [4].
Therefore, the issue of pathologic fractures should be
considered more important than normal traumatic
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any medium, provided the original work is properly cited.fractures in the orthopaedic field of the treatment of fra-
gility fractures.
Most pathologic fracture studies have been conducted
based on tumour-associated patients and hospital-based
data, and no nationwide epidemiological survey of
pathologic fractures has been performed to date. This
study therefore aimed to perform a nationwide epide-
miological survey of pathologic fractures in Taiwan
independent of cause and calculate the medical utiliza-
tion, which could be of use to policymakers in Taiwan
in redistributing medical resources and promoting more
aggressive treatment.
Methods
Source, security, and quality control of data
Taiwan launched a single-payer NHI Program in 1995,
and as of 2007, 22.60 million Taiwanese people of a
total population of 22.96 million were enrolled in this
program; foreigners in Taiwan are also eligible for inclu-
sion. In order to respond toc u r r e n ta n de m e r g i n g
health issues rapidly and effectively, in cooperation with
the National Health Insurance Bureau (NHIB), the
National Health Research Institute (NHRI) established a
nationwide research database, and the NHIB established
a uniform system to control the quality of medical ser-
vices and coding.
The NHRI safeguards the privacy and confidentiality
of patients included in the database and routinely trans-
fers health insurance data from the NHIB to enable
health researchers to analyse and improve the health of
Taiwan’s citizens. The National Health Insurance (NHI)
database contains registration files and original claims
data for reimbursement, and access to the National
Health Insurance Research Database (NHIRD), which
was derived from this system by the NHIB and is main-
tained by the NHRI, is provided to scientists in Taiwan
for research purposes.
Data protection and permission
Any data in the NHIRD that could be used to identify
patients or care providers, including medical institu-
tions and physicians, are scrambled before being sent
to the NHRI for database inclusion, and the data are
further scrambled before being released to researchers.
Theoretically, it is impossible to query the data alone
to identify individuals at any level using this database.
The protocol of this study was evaluated by the NHRI,
who gave their agreement to the planned analysis of
the NHIRD (Application and Agreement Number:
99005). This study was also approved by the Institu-
tional Review Board (IRB) of Taoyuan General
Hospital, which has been certificated by the Depart-
ment of Health, Taiwan (IRB Approval Number:
TYGH098033).
Data selection and definition of pathologic fractures
All claimants of Taiwan’s NHI Program at any time dur-
ing 2008 were included in the target population of this
descriptive cross-sectional study. In order to investigate
the treatment incidence of pathologic fractures among
hospitalized subjects of the target population, the regis-
tration and claims data of inpatient expenditure by
admission were examined and the concomitant ICD-9-
CM diagnosis codes were evaluated and classified into
seven major categories. Pathologic fracture of the
humerus was defined as the diagnosis code 733.11 and
pathologic fracture of the distal radius/ulna was coded
733.12. The third category, pathologic fracture of verteb-
rae, was coded 733.13. Pathologic fractures of the neck
of the femur, any other part of the femur, and the tibia/
fibula were coded 733.14, 733.15 and 733.16, respec-
tively. The seventh category, pathologic fractures of
unspecified or other sites, included all other cases and
was coded 733.1, 733.10 or 733.19.
Statistics
The method of back-projection was used to estimate the
unobserved past incidences of various pathologic frac-
tures, which are expressed as the proportions of the tar-
get population in Taiwan. The independent t-test and
Pearson’sc h i - s q u a r et e s tw e r eu s e df o rs i m p l ed e s c r i p -
tive comparison of differences in the indicators of medi-
cal utilization and bony surgery rates between genders.
Results
Treatment incidence of pathologic fractures of various
locations and associated metabolic disorders
According to the previously-defined selection criteria,
3,094 subjects who were hospitalized for pathologic frac-
ture in 2008 were identified. Of the 3,094 studied sub-
jects, 5,244 incident cases of various categories of
pathologic fracture were identified within one year (i.e.,
in 2008, Taiwan) (Table 1), which included 3,003 recog-
nized cases of fracture in six major locations and 2,241
almost concomitant with the above but unspecified
cases. By dividing the number of cases by the number of
beneficiaries of the same age and gender in 2008, the
estimated incidence of pathological fracture requiring
hospitalization in Taiwan categorized by fracture loca-
tion was calculated. The treatment incidence of most of
the variously-located pathologic fractures increased with
age for both genders, and this trend was very obvious
for fractures of the vertebrae and femoral neck. In gen-
eral, the estimated incidence of pathologic fracture in
Taiwan was 22.89 per 100,000 people based on the
nationwide health insurance hospitalization data, and
the individual incidence of fracture of the humerus, dis-
tal radius/ulna, vertebrae, femoral neck, other femoral
location, and tibia/fibula was 0.67, 0.08, 10.58, 1.11,
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Page 2 of 60.56, and 0.11 per 100,000 people, respectively. Worthy
of note, a high proportion of unspecified or alterna-
tively-located pathologic fractures was noted, the esti-
mated incidence being 9.78 per 100,000 people.
Medical utilization for the various identifiably-located
pathologic fractures and concomitant bony surgery
Table 2 shows the average medical utilization for
patients hospitalized with identifiably-located pathologic
fractures in Taiwan. For humeral pathologic fractures,
the average hospital stay was 43. 9 ± 42.9 days and the
associated direct medical cost was US$11,049 ± 12,730
(currency conversion rate: US$1 = NT$32). For distal
radial/ulnar, vertebral, femoral neck, other part of the
femur, and tibial/fibular pathologic fractures, patients
stayed in hospital for 31.1 ± 32.9, 29.4 ± 34.4, 43.2 ±
41.2, 42.4 ± 38.1 and 42.0 ± 32.8 days, respectively, and
the associated direct medical cost was US$9,181 ±
12,114, US$6,250 ± 8,021, US$9,619 ± 8,906, US$10,646
± 11,024 and US$9,403 ± 9,882, respectively. The differ-
ences in medical utilization between genders were also
analysed, and a significant finding was that for cases of
pathologic fracture of the distal radius/ulna or vertebrae,
more medical resources (in terms of a longer length of
stay and a greater medical cost) were required for male
patients.
Finally, the requirement for surgical intervention in
hospitalized pathologic fracture cases was investigated
(Table 3), and the percentage of cases in which bony
surgery was performed for pathologic fractures of the
humerus, radius/ulna, vertebrae, femoral neck, other
part of the femur, and tibia/fibula was 31.2%, 44.4%,
11.3%, 46.5%, 48.4%, and 52.5%, respectively. The differ-
ence in the bony surgery rate for each fracture category
between genders was investigated, and no statistically
significant differences were noted. The bony surgery
procedures were stratified into instrument fixation, pros-
thesis application, bone biopsy or excision, and bone-
grafting or other bone plastic procedures, and surgical
interventions in the spinal area were further classified as
anterior or posterior-lateral fusion procedures.
Discussion
The exact incidence of bone metastasis is unknown, but of
the estimated 1.2 million new cases of cancer diagnosed
annually in the US, more than 50% will eventually demon-
strate skeletal metastases [5], and it is estimated that
350,000 people die of bone metastases annually in the US
[6]. National prevalence estimates were produced from the
2000-2004 MarketScan databases of the USA, and of
396,200 oncology patients, 18,042 (4.6%) were identified as
having bone metastasis. Applying the projection metho-
dology, 5.3% of these patients were projected to have bone
metastases [7]. This study revealed that the estimated inci-
dence of treated pathologic fracture is 22.89 per 100,000
people annually in Taiwan. More epidemiological cohort
surveys of the oncology registry data in Taiwan are needed
in order to compare the cumulative incidence of patholo-
gic fracture with that in other countries.
The incidences of pathologic fractures of some specific
locations have rarely been reported. One epidemiological
survey of 401 fractures of the shaft of the humerus
revealed that 8% of the fractures were pathologic [8]. A
retrospective 36-year chart review of all patients with
metastatic bone disease admitted to a single tertiary
orthopaedic referral centre was conducted, which identi-
fied 601 females and 580 males (mean: 60 years) with
metastatic bone disease, of the femur (28%) and spine
(29%) in the main [9]. In the present study of pathologic
fractures in Taiwan requiring hospitalization, the spine
was found to be the most common location, followed by
parts of the femur and the humeral area. However, a
high proportion (42.7%) of cases of pathologic fracture
at unspecified sites was noted, and, possibly through
some administrative encouragement means provided by
the Taiwan’s health insurance authority, the accuracy of
coding should be improved to ensure the validity of the
data of Taiwan’s health insurance system.
Table 1 Treatment incidence of pathologic fracture cases categorized by anatomic location in Taiwan, 2008 (valid
n = 5244)
Total Inc.* for those Inc.* for those Inc.* for those
enrolled cases aged 0-19.9 aged 20-49.9 aged 50 or over
Category of fracture Cases Inc. * Female Male Female Male Female Male
Pathologic fracture of humerus (733.11) 154 0.67 0.04 0.21 0.30 0.18 1.82 2.03
Pathologic fracture of distal radius and ulna (733.12) 18 0.08 0.00 0.04 0.05 0.05 0.25 0.10
Pathologic fracture of vertebrae (733.13) 2424 10.58 0.04 0.14 1.91 1.33 41.97 29.29
Pathologic fracture of neck of femur (733.14) 254 1.11 0.04 0.14 0.39 0.31 3.63 3.08
Pathologic fracture of other specified part of femur (733.15) 128 0.56 0.12 0.14 0.19 0.22 1.72 1.41
Pathologic fracture of tibia and fibula (733.16) 25 0.11 0.00 0.04 0.04 0.09 0.28 0.26
Pathologic fracture, other specified or unspecified sites (733.1,733.10, 733.19) 2241 9.78 0.27 0.53 2.49 2.21 33.36 29.06
*Inc.: treatment incidence, 1/100,000.
Lee et al. BMC Health Services Research 2011, 11:230
http://www.biomedcentral.com/1472-6963/11/230
Page 3 of 6Table 2 Medical utilization for subjects with a pathologic fracture of an identifiable location in Taiwan, 2008 (valid n = 3003)
Medical Cost ($NT), mean, (S.D.) Length of Stay (days), mean, (S.D.)
In general Female Male In general Female Male
Fracture location cases mean (S.D.) cases mean (S.D.) cases mean (S.D.) P * cases mean (S.D.) cases mean (S.D.) cases mean (S.D.) P *
Pathological Fx of Humerus 154 353,575 407,372 76 360,005 346,344 78 347,309 461,335 0.357 154 43.9 42.9 76 48.3 45.7 78 39.6 39.8 0.402
Pathological Fx of Distal Radius/Ulna 18 293,803 387,673 11 178,740 210,325 7 474,616 538,219 0.009 18 31.1 32.9 11 21.0 19.0 7 47.0 44.5 0.020
Pathological Fx of Vertebrae 2424 200,015 256,668 1,451 186,175 245,394 973 220,654 271,435 0.005 2424 29.4 34.4 1,451 26.3 30.3 973 33.9 39.4 0.000
Pathological Fx of Neck of Femur 254 307,807 284,991 139 303,879 248,781 115 312,555 324,480 0.324 254 43.3 41.2 139 45.7 42.7 115 40.4 39.5 0.327
Pathological Fx of Other Part of Femur 128 340,675 352,755 69 350,874 394,534 59 328,747 299,516 0.270 128 42.4 38.1 69 43.5 42.4 59 41.3 32.7 0.165
Pathological Fx of Tibia and Fibula 25 300,888 316,227 11 290,137 309,024 14 309,335 333,140 0.451 25 42.0 32.8 11 43.6 26.5 14 40.6 38.0 0.119
S.D.: standard deviation
*Descriptive comparison of differences between genders was performed by the independent t-test.
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6Few studies of the medical burden of bone metastatic
disease or pathologic fractures have been performed, but
the cost of bone metastasis in cancer patients was esti-
mated to be $12.6 billion dollars per year (17% of the total
direct medical cost) in the US from 2000 to 2004 [7]. In
the Netherlands, a retrospective cost analysis study asso-
ciated with bone metastases in patients with prostate can-
cer showed an average cost of 6,973 Euros per patient to
treat skeletal-related events [10]. We calculated in this
study the mean direct medical cost and administrative uti-
lization for individual pathologic fracture cases in Taiwan,
to compare with individual non-pathologic fracture cases
in Taiwan according to Taiwan Diagnoses Related Groups
(TW-DRGs), the new payment regulations in Taiwan that
have been in place since January 1st 2010. For example, a
lower-extremity (excepting the femur) or humeral fracture
can be paid US$583-3,109, with an average of 6-8 days in
hospital being allowed, and for a hip or femoral fracture,
the cost is US$952-3,691, with an average stay of 7-10
days [11]. These values are much lower than those esti-
mated in the present study. However, owing to the scarcity
of published literature on this topic, we were not able to
adequately compare Taiwanese expenditures against
expenditures of other nations, for bone metastasis or for
the costs of follow-up treatment for metastatic bony
events. Future studies concerning medical economic issues
should be encouraged in order to assist public health pol-
icymakers in making policy decisions worldwide.
Several decades ago, more conservative treatments for
pathologic fractures were accepted. A study evaluating
the results of treating seventy-two pathologic long-bone
fractures revealed that only 25% of upper-extremity and
57.5% of lower-extremity pathologic fractures were
treated with internal fixation, and better outcomes were
noted for those treated by internal fixation than those
treated by other means [12]. Recently, surgical treatment
has been employed for impending or existing pathologic
fractures. In a recent prospective study based upon the
skeletal metastasis register of the Scandinavian Sarcoma
Group, pathologic fracture was found to be an indepen-
dent negative prognostic factor of one-year survival [13].
Another recent study showed that of 2,776 patients with
intracapsular fractures of the proximal femur, 18% of
patients were treated non-surgically. Included in the
group of patients who were treated conservatively were
children, patients with cardiac problems, mental pro-
blems, stroke, renal failure, and multiple disseminated
malignancies, and patients who chose non-surgical treat-
ment [14]. In comparison with the proportions of cases
in which surgical intervention was performed reported in
the above-mentioned studies, the surgical rate for patho-
logic fracture in Taiwan was found in this study to be on
a par with that reported for other countries for the upper
limbs but lower for the lower limbs. This study took a
nationwide overview of pathologic fractures registered in
the health insurance inpatient database rather than
examining the outcomes of patients referred to hospital
for treatment in Taiwan. More conservative treatment in
some community hospitals and less adequate referral
processes to tertiary treatment centres are possible causes
of this difference, and further studies should be per-
formed in the future to investigate this issue.
There were some principal limitations in the present
study. This was a one-year cross sectional study investi-
gating the characteristics of pathological fractures
requiring hospitalization based on the NHI dataset.
Table 3 Distribution of surgical intervention for pathologic fractures of an identifiable location in Taiwan, 2008 (valid
n = 3003)
Pathologic Fx
of Humerus
(n = 154)
Pathologic Fx of
Distal Radius/Ulna
(n = 18)
Pathologic Fx
of Vertebrae
(n = 2424)
PathologicFx of
Neck of Femur
(n = 254)
Pathologic Fx of
Other Part of Femur
(n = 128)
Pathologic Fx of
Tibia and Fibula
(n = 25)
n (%) n (%) n (%) n (%) n (%) n (%)
Bony surgery performed?
Yes 48 (31.2%) 8 (44.4%) 273 (11.3%) 118 (46.5%) 62 (48.4%) 13 (52.0%)
No 106 (69.8%) 10 (55.6%) 2151 (88.7%) 136 (53.5%) 66 (51.6%) 12 (48.0%)
Bony surgery strategy:
1. Instrument fixation 41 8 58 52 13
2. Spine fusion 91*
164**
3. Prosthesis 3 0 51 5 0
4. Excision, biopsy 39 6 98 46 38 9
5. Bone-grafting, bone
plastic
Surgery
65 2 8 9 1 1 4
*anterior fusion procedures
**posterior-lateral fusion procedures
Note-There were no statistically significant differences between genders, for bony surgery rates, tested separately for each fracture category.
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bank in Taiwan; therefore, prospective survival analysis
for subsequent events, including complications of sur-
gery or death, was not able to be performed. Further
information and investigations are needed in the future.
Conclusion
We observed in our study that medical utilization for
pathologic fracture cases was higher in Taiwan com-
pared to that reported for other nations. However, we
also noted less-aggressive surgical intervention for
patients hospitalized with pathologic fractures in Tai-
wan, in comparison with other countries.
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